• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Knopp Kevin J. bought $64,788 worth of shares (15,000 units at $4.32), increasing direct ownership by 2% to 707,733 units (SEC Form 4)

    5/14/25 4:28:02 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials
    Get the next $MASS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Knopp Kevin J.

    (Last) (First) (Middle)
    C/O 908 DEVICES INC.
    645 SUMMER STREET

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    908 Devices Inc. [ MASS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/14/2025 P(1) 15,000 A $4.3192(2) 707,733 D
    Common Stock 541,223 I See Footnote(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reported purchases are matchable with sales by the reporting person on February 3, 2025 mandated by 908 Devices to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units; however, the reporting person did not realize any profit in connection with such short-swing transactions, and thus no disgorgement is owed to 908 Devices.
    2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.25 to $4.40, inclusive. The reporting person undertakes to provide to 908 Devices Inc., any security holder of 908 Devices Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
    3. The shares are owned directly by The Kevin J. Knopp Irrevocable Trust of 2018. The reporting person's brother-in-law is the trustee of The Kevin J. Knopp Irrevocable Trust of 2018 and has sole voting and dispositive control with respect to all securities held by such trust. The reporting person may be deemed to be the beneficial owner of the securities held by The Kevin J. Knopp Irrevocable Trust of 2018.
    Remarks:
    /s/ Michael S. Turner, as Attorney-in-Fact 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS

    DatePrice TargetRatingAnalyst
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    2/7/2023$14.00Overweight
    Stephens
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Knopp Kevin J. bought $66,596 worth of shares (15,000 units at $4.44), increasing direct ownership by 2% to 722,733 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/19/25 4:37:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Director Spoto Mark bought $42,850 worth of shares (10,000 units at $4.29), increasing direct ownership by 19% to 62,971 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/15/25 4:52:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • President and CEO Knopp Kevin J. bought $64,788 worth of shares (15,000 units at $4.32), increasing direct ownership by 2% to 707,733 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/14/25 4:28:02 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

      908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as

      3/2/22 4:30:00 PM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care